Researchers used a combination of encorafenib, binimetinib and cetuximab to treat CRC. Encorafenib prevents mutant enzymes from stimulating cell growth, binimetinib brings those mutated enzymes under control to regulate proliferation and cetuximab binds the epidermal growth factor receptor.
When used together the three therapies improved progression-free survival rates in 30 patients for whom previous treatments were ineffective. Specifically, 48 percent of patients had a reduction in tumor size, with three patients completely eradicating their cancers.
The study did not provide an overall survival rate, however.
More articles on gastroenterology:
Virtual Incision Corp. raises $18M in series B funding for colon resection surgical robot: 5 things to know
Tumor cell-detecting blood test accurately discovers CRC
7 highlights from Pfizer’s survey on ulcerative colitis
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.